secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001641172-25-003334
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics submits Phase II concussion trial protocol to NZ ethics committee
---------------------------------------------------------------------------

- Submitted clinical trial protocol to Health and Disability Ethics Committee (HDEC) in New Zealand for Phase II trial of ONP-002 for mild traumatic brain injury.
- Pending HDEC approval, expects to initiate patient enrollment at Christchurch Hospital, one of the busiest emergency departments in Australasia.
- ONP-002 is an intranasal neurosteroid therapy; no approved pharmaceutical exists for concussion, an unmet medical need.
- Phase I study showed safety and tolerability; Phase II will evaluate efficacy in mTBI patients.
- Company plans to expand global clinical footprint with sites in both Australia and New Zealand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000164117225003334/0001641172-25-003334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000164117225003334/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer